Cutaneous lymphocyte-associated antigen (CLA + ) T cells are specialized for skin homing and represent the main T-cell population in atopic dermatitis (AD) lesions. CLA + is expressed on the surface of circulating CD45RO + memory T cells and most skin-infiltrating T cells. Mechanistic studies and thus treatment advancements are limited by the need of large number of skin biopsies. Circulating CLA + T cells may be a reliable surrogate marker of the inflammatory events occurring in the skin, and thus, the evaluation of CLA + T cells in the blood may eliminate the need for skin biopsies. Preliminary work in AD has established that disease-associated T-cell abnormalities can be approached by either a study of skin lesions or activated CLA + T-cell subsets in peripheral blood. Future studies in adults and children, across different skin disorders, correlating blood and skin phenotypes and determining skin-homing T-cell functional properties are needed to establish whether CLA + memory subsets can be used as biomarkers and a substitute for skin biopsies. This review summarizes the latest advancements reached on circulating CLA + in AD and the great potential they harbor in understanding AD mechanisms.
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The functional compartmentalization of T cells into nonlymphoid peripheral tissues and the existence of the regional cutaneous immune system are known for decades (1) . However, the applicability of this physiological T-cell extravasation and migration into tissues for translational research approaches in dermatology is still in early stages. Studies of the cutaneous immune system in atopic dermatitis (AD), the most common inflammatory skin disease (2, 3), allowed to identify key skin disease mechanisms along with cellular and molecular players in skin from patients with AD (4).
Two leading theories have been proposed for AD pathogenesis. The 'outside-in' theory, supported by the finding of filaggrin mutations (5) , suggests that a dysfunctional epidermal barrier initiates the disease with secondary immune abnormalities. The 'inside-out' hypothesis, on the other hand, advocates for the immune dysregulation, and particularly Tcell disturbances, as driving the disease, with barrier changes being an epiphenomenon (5, 6) . Accumulated evidence supports a mutual contribution of these mechanisms in AD (7) (8) (9) , but regardless of the temporal order in which they occur, the pathologic skin phenotype of AD is perceived as T-celldriven, as supported by clinical and tissue disease reversal with broad and narrow T-cell-targeting treatments (10) (11) (12) (13) (14) (15) (16) .
The identification of the trafficking receptor cutaneous lymphocyte-associated antigen (CLA), as a cell surface marker that is expressed on 15% of human circulating T cells and enables a differential migration of T cells to the skin, is a hallmark for functional studies of the cutaneous immune system (17, 18) . The CLA was identified as a carbohydrate expressed on the surface of circulating CD45RO + memory T cells, and on most (>90%) skin-infiltrating T cells, contrary to other inflamed organs (17) . As in many occasions, this serendipitous discovery led to accumulation of a body of knowledge that is highly informative for translational immunology and biomarker research in AD. The CLA is part of a complex of adhesion molecules and chemokine receptors that allows T cells to selectively migrate to skin, in either homeostatic or inflammatory conditions, by binding to endothelial cell wall via adhesion molecules or ligands. The molecular interactions between CLA/E-selectin, lymphocyte function-associated antigen-1 (LFA-1)/intercellular adhesion molecule-1 (ICAM-1), very late antigen-4 (VLA-4)/vascular cell adhesion protein-1 (VCAM-1), and chemokine ligands for chemokine, C-C motif, receptor (CCR) 10, CCR4, CCR6, and CCR8 constitute a code bar system enabling skin infiltration (19) . While naive T cells do not express CLA, it is induced during the conversion of na€ ıve to memory phenotype (20) . Although originally thought to be exclusively expressed on effector CD45RO + CCR7
À (Tem) T cells (20, 21) , it is now well established that all memory compartments of the immune system present the CLA (22) . Most T cells in AD skin lesions are CLA + CD45RO + memory cells (12) (13) (14) . Circulating CLA + T cells are expanded in AD, respond to skin-associated allergens, infiltrate skin lesions, and are central players in the initiation and perpetuation of AD lesions (23) (24) (25) . Additionally, it has been shown that bacterial toxins increase CLA expression in superantigen-mediated diseases and that AD severity is correlated with CLA + T-cell-attracting chemokines in serum (4, 26) .
It is important to emphasize that the relevance of circulating CLA + T cells in dermatology relies not only on their capacity to selectively migrate to skin, but also on the fact that these circulating memory T cells might reflect the cutaneous immune responses (19) . From this point of view, one could consider them as a window to 'cutaneous' T cells. The easy access to these T cells from peripheral blood during active disease or disease flares creates an opportunity for ex vivo, less invasive, translational approaches that might be particularly beneficial in pediatric patients with AD, where skin sampling is particularly challenging (27) .
Recirculation of CLA + T cells between skin and blood and the anti-LFA-1 effects in AD
The interaction of the integrin family member, LFA-1, with ICAM-1 is one of the mechanisms involved in the transendothelial migration of CLA + T cells (28) . Clinical validation of this mechanism came from studies with efalizumab, an LFA-1-targeting monoclonal antibody that blocks the LFA-1/ICAM-1 interaction. Although efalizumab treatment led to reduction of cutaneous CLA + memory T cells (29) , and AD clinical improvement (30) , there was a fourfold increase in blood circulatory CLA + effector memory T cells (31) . In the context of a normal recirculation between peripheral tissues (e.g., skin) and blood, inflammatory cells can migrate back from end organs to the blood.
Thus, during skin inflammation in AD the prevention of CLA + T-cell skin entry by inhibition of the LFA-1/ICAM-1 interaction leads to secondary accumulation in the blood coupled with CLA + T-cell 'reverse' migration from skin to blood through lymphatics (19) . A similar effect was documented in psoriasis where successful efalizumab treatment induced an increase in peripheral blood memory T cells (32) . Thus, clinical rebound upon drug discontinuation, observed in both AD and psoriasis, might be explained by a quick migration of these accumulating CLA + T cells from the blood into the skin (30, 33) . This observation also suggests that the circulating CLA + T cells in AD present phenotypic features that link them to the cutaneous inflammation in AD lesions, as discussed below, suggesting the role of this minor subset of leukocytes as peripheral cellular biomarkers of AD (Fig. 1) . were significantly more activated in patients with AD (34) . This observation provides a potential explanation to the short disease remissions and less optimal treatment responses seen in patients with AD, as compared to other inflammatory skin disease populations such as psoriasis (39) . The increased CLA À ('systemic') activation might be associated with the noncutaneous atopic manifestations commonly seen in AD (40) . Indeed, our data showed that~80% of patients with AD who had increased CLA À T-cell activation suffered from asthma, food allergies, or environmental allergies (34) . Additionally, increased 'systemic T-cell activation may also account for the systemic comorbidities that are now becoming increasingly recognized in patients with severe AD (41) (42) (43) .
In patients with AD allergic to house dust mite (HDM), the response to HDM within the circulating memory T-cell compartment is restricted to the CLA + T-cell compartment but not involving CLA À T cells (35) . Interestingly, in asthma with or without associated AD, the HDM-dependent proliferation slightly predominated in the CLA À when compared to the CLA + subset (35) . Besides HDM, patients with AD also respond to birch pollen (44) and to the auto-allergen Hom s 2, the human transcriptional coactivator a-nascent polypeptide-associated complex (a-NAC; an intracellular protein) that induces preferential proliferation of CLA + cells (45) . CLA + T-cell responses to skin-related antigens in AD have been also demonstrated for Staphylococcus aureus (S. aureus) (46) . Children with acute AD showed an increased frequency of circulating CLA + T cells bearing the
S. aureus-related T-cell receptor variable Vb segments (46).
These results were also confirmed in adults with AD (36, 47, 48) . CLA + T cells were also implicated in the neurogenic inflammation in AD. Compared to controls (and patients with psoriasis), in AD, circulating CLA + T cells produce higher levels of the IL-31 cytokine, which is involved in pruritus induction (49) . Intriguingly, patients with AD showed higher increases in IL-4-, IL-5-and IFN-c-producing CLA + lymphocytes during psychological stress, as compared to controls exposed to similar conditions (50) . Similarly, circulating CLA + lymphocytes from patients with AD incubated with calcitonin gene-related peptide (CGRP), but not with other neuropeptides, showed increases in IL-13 and HLA-DR activation among CLA + but not CLA À T cells (51) .
Peripheral AD cellular phenotyping in adults and children
The need for large skin biopsies to define polar T-cell subsets limits the feasibility of cytokine measurements from patients with AD, particularly children. As CLA + memory cells are the main population of T cells found in AD skin lesions (4), evaluation of polarized, activated circulating CLA + memory T-cell subsets may provide a surrogate to skin immune phenotyping. We have recently phenotyped blood of adults and children with AD on a single-cell level using flow cytometry. We showed that adults with AD (compared with healthy controls) are characterized by a skin-selective Th2/Tc2 and Th22/Tc22 expansion, accompanied by a CLA + -selective Th1/Tc1 defect (22) . Our results indicated that skin-homing CLA + cytokine dysregulation is mostly pronounced in Figure 1 Circulating CLA + T cells are migrating to skin through a complex process of rolling and adhesion, in which CLA + /E-selectin interaction is one step. A portion of these memory T cells migrate back to the blood through the lymphatic system, and can eventually recirculate back to the skin. Due to this recirculation phenomenon, studying CLA + subsets in the blood of patients with AD may reflect immune activation and polar T-cell subset differentiation occurring in the skin in response to diverse antigenic stimuli. CLA, cutaneous lymphocyte antigen.
patients with severe and/or extrinsic (elevated IgE levels) AD (22) . Revisiting our data shows that circulating CLA + Tem and Tcm cells are highly correlated not only with AD severity (by SCORing of AD/SCORAD) ( Fig. 2A, B ), but also with total IgE levels in serum (Fig. 2C, D) . This suggests that CLA + might function as a biomarker of several disease aspects. Importantly, circulating CLA + effector memory T cells were significantly correlated with skin-infiltrating CD3 + (T cells) and CD1a + (Langerhans) cells (Fig. 2E, F) , underlining circulating CLA + subset potential as a disease biomarker. We next studied T-cell activation and polar cytokine subsets in the pediatric population (27) . Studies of pediatric AD are technically challenging, due to difficulties to obtain large enough blood samples, and even more so getting skin samples. Nevertheless, studying infants and young children with AD is extremely important for understanding mechanisms of disease initiation as compared to those of chronic disease seen in adults with AD (10, 27) . Our blood phenotyping in young children of less than 5 years old with disease duration up to 6 months showed that early pediatric AD is characterized by a skin-selective Th1/Th2 imbalance and that Th22/ IL-22 expansion in blood is solely a feature of long-standing, chronic disease in adults with AD (27, 52) . As AD usually precedes the development of other atopic disorders (53, 54) , these data have important therapeutic implications for treatment of early pediatric AD and possibly prevention of the atopic march, suggesting that early targeting of the Th2/Tc2 axes (i.e., dupilumab) rather than Th22/Tc22 pathways may not only provide a beneficial intervention for children with AD, but also possibly prevent the entire atopic march (14, 15) . Importantly, the most prominent skin-homing immune alterations (as compared with age-matched controls) are detected in the very early phase/young pediatric age group (0-3 years old) of AD rather than 'later' pediatric stages of 3-to 6-year-old group (55) . This emphasizes the need to focus on the very young patient group when studying characteristic mechanisms of AD initiation.
Conclusion
The functional properties of circulating CLA + T cells were also confirmed in other different T-cell-mediated skin disorders such as contact dermatitis, drug-induced allergic reactions, vitiligo, psoriasis, and herpes simplex virus infection, where T-cell responses to relevant antigens/allergens are driven by the skin-homing CLA + subset (19, (56) (57) (58) . In alopecia areata, circulating CLA + T cells were shown to be elevated, decreasing upon clinical improvement with oral corticosteroid therapy (59) . Keeping in mind that a comprehensive blood-skin correlation is still needed to verify compartments' immune-skewing similarities, establishing circulating CLA + memory cells as peripheral cellular biomarkers in various skin diseases, and thus to possibly eliminate the need for skin biopsies, harbors great potential to affect the dermatology field for both practitioners and patients.
Author contributions
Tali Czarnowicki was responsible for data acquisition in studies presented under her name, main writing of the manuscript, figure design, and critically revising the manuscript for important intellectual content. Luis F. Santamaria-Bab ı was responsible for writing of the manuscript, figure design, and critically revising the manuscript for important intellectual content. Emma Guttman-Yassky was responsible for writing of the manuscript and critically revising the manuscript for important intellectual content.
